Jin Medical announces initiation of construction of new manufacturing facility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 10 2024
0mins
New Manufacturing Facility: Jin Medical has begun construction on a new manufacturing facility in Chuzhou City, Anhui Province, China, dedicated to producing high-end wheelchairs and electric wheelchairs.
Innovative Production: The establishment of the Chuzhou JinMed plant aims to enhance production capabilities and introduce innovative products, reinforcing JinMed's position in the assistive technology industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZJYL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZJYL
About ZJYL
Jin Medical International Ltd is a holding company mainly engaged in the design and manufacturing of wheelchairs. The Company, through its wholly owned subsidiaries, is primarily engaged in the design, development, manufacturing and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's wheelchair product category includes mid, high and low-end wheelchairs. The wheelchair components include wheels and brakes, which are sold to customers for after-sales service. The living aids product category consists of oxygen concentrators, bath aids and rehabilitative devices. The Company mainly distributes its products in domestic and overseas markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Continue Reading
Jin Medical International to Host Strategic Discussion
- Executive Strategic Discussion: Jin Medical's CEO and management team will host a strategic discussion on February 1, 2026, at 8 PM EST, aimed at sharing recent strategic priorities and long-term growth considerations, which is expected to enhance investor confidence.
- Website Update Launch: The company has launched its updated corporate website, providing a webcast of the strategic discussion, thereby increasing information transparency and offering investors a more convenient channel to access company updates.
- Manufacturing Capacity Expansion: Jin Medical operates two manufacturing plants in Jiangsu Province totaling approximately 230,000 square feet and is establishing a new facility of 430,000 square feet in Chuzhou, Anhui Province, demonstrating the company's proactive response to future market demand.
- International Distribution Network: Jin Medical collaborates with over 40 domestic distributors and more than 20 international distributors, primarily selling over 30 lightweight and ergonomic wheelchair models to Japan and China, further solidifying its leadership position in the rehabilitation medical equipment market.
Continue Reading